search
Back to results

Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids (Lune2)

Primary Purpose

Leiomyoma

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
myomectomy
embolisation
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Leiomyoma focused on measuring Leiomyoma, Uterine Artery Embolization, Surgery, childbearing age, Fertility, Noninferiority trial

Eligibility Criteria

18 Years - 43 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women aged ≥ 18 and ≤ 43 years old
  • At least one interstitial fibroid more than 3 cm on MRIat MRI)
  • with symptoms: genital bleeding, chronic pelvic pain or heaviness, anemia, or infertility > 1 year.
  • With immediate desire to conceive
  • without assisted reproductive indication: no tubal infertility, menstrual irregularities, hydrosalpinx, endometriosis, adenomyosis, or male infertility.
  • Patient with health insurance, who can read and understand French and who has given written consent

Exclusion Criteria:

  • Ongoing regnancy
  • Emergency Situation
  • Contraindication to surgery or uterine embolization: allergy to contrast medium , renal failure, immunodeficiency, contraindication to anesthesia, subserosal or submucosal pedunculated fibroids, fibroids with largest diameter inside of the uterine cavity

Sites / Locations

  • Département de Médecine de la Reproduction, Centre Hospitalier Régionnal Universitaire de Montpellier

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

myomectomy

embolisation

Arm Description

Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route

Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter > 500µm)

Outcomes

Primary Outcome Measures

Number of live birth in a year of fertility attempt
Women will be allowed to attempt fertility 6 months after treatment. Effective fertility attempts will be prospectively followed. Final fertility will be assessed one year later.

Secondary Outcome Measures

number of adverse effects on fertility (ovarian reserve markers)
number of adverse effects on fertility (state of the uterine cavity)
number of adverse effects on fertility (state of the endometrium
Improvement of symptoms related to fibroids With UFS-QoL questionnaires
Improvement of symptoms related to fibroids With UFS-QoL questionnaires
Improvement of symptoms related to fibroids With UFS-QoL questionnaires
Improvement of symptoms related to fibroids With UFS-QoL questionnaires
Quality of life With QSF questionnaires, a French version of the WHQ questionnaire
Quality of life With QSF questionnaires, a French version of the WHQ questionnaire
Quality of life With QSF questionnaires, a French version of the WHQ questionnaire
Quality of life With QSF questionnaires, a French version of the WHQ questionnaire
Number of adverse effects during pregnancy : Rate of Miscarriage
Number of adverse effects during pregnancy : extra-uterine pregnancy
Number of adverse effects during pregnancy : small for gestational age
Number of adverse effects during pregnancy : foetal death
Number of adverse effects during pregnancy : uterine rupture
Number of adverse effects during pregnancy : abnormal placental position and implantation
Number of adverse effects during pregnancy : preterm delivery
Number of adverse effects during pregnancy : delivery hemorrhagy
number of adverse effects in the newborn
Rate of small for gestational age, delivery presentation, health of newborn children (Apgar score, cord pH, admission in the neonatology service)

Full Information

First Posted
July 20, 2015
Last Updated
April 16, 2021
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT02577055
Brief Title
Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids
Acronym
Lune2
Official Title
Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
October 16, 2019 (Actual)
Study Completion Date
October 16, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Purpose of this study: To establish the superiority of myomectomy versus Uterine Artery Embolization, in women with multiple symptomatic fibroids and no other infertility factor, seeking to conceive.
Detailed Description
Background: The use of uterine artery embolization (UAE) to treat symptomatic fibroids in women seeking future fertility remains a matter of debate, because of possible adverse effects on ovarian reserve and embryo implantation. In women with associated infertility factors, not eligible for myomectomy, poor fertility was obtained after UAE. On the other hand, fertility of women eligible for surgical myomectomy, deciding to have a UAE, compares favourably with the fertility obtained after myomectomy. Study design: Eligible women will be explored to pull out any other infertility factors such as: tubal factors (no hydrosalpinx at MRI, tubal permeability assessed by hysterosalpingography and/or negative serology of for Chlamydia) Endometriosis (clinical history and examination, MRI) Ovarian factors (normal AMH dosage, and Antral follicular count) Male factors (normal spermogram of the Partner if possible) Women will be treated with fertility sparing ultra selective uterine artery embolization, or surgical removal of multiple myomas. A six months convalescence/cicatrisation period will be respected, then women will be allowed to intend to conceive. Several elements will be prospectively followed: Spontaneous pregnancy from 6 months to 18 months after treatment Pregnancy outcomes Symptoms and quality of live with UFS-QoL and WHQ questionnaires, at 3, 6, 12 and 18 months after treatment Uterine size with MRI, before and 3 months after treatment. Aspect of the uterine cavity with hysteroscopy before and 3 months after treatment. Ovarian reserve with AMH dosage, and Antral follicular count before and 3 months after treatment. Volume and molecular pattern of the endometrium at the implantation window before and 3 months after treatment (optional). Treatment's adverse effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leiomyoma
Keywords
Leiomyoma, Uterine Artery Embolization, Surgery, childbearing age, Fertility, Noninferiority trial

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
9 (Actual)

8. Arms, Groups, and Interventions

Arm Title
myomectomy
Arm Type
Active Comparator
Arm Description
Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route
Arm Title
embolisation
Arm Type
Experimental
Arm Description
Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter > 500µm)
Intervention Type
Procedure
Intervention Name(s)
myomectomy
Intervention Description
Surgical ablation of all fibroids
Intervention Type
Procedure
Intervention Name(s)
embolisation
Other Intervention Name(s)
Fertility sparing ultra selective uterine artery embolization
Intervention Description
Embolisation of the peri-myoma vascular network, with non-resorbable particles of >500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
Primary Outcome Measure Information:
Title
Number of live birth in a year of fertility attempt
Description
Women will be allowed to attempt fertility 6 months after treatment. Effective fertility attempts will be prospectively followed. Final fertility will be assessed one year later.
Time Frame
18 months
Secondary Outcome Measure Information:
Title
number of adverse effects on fertility (ovarian reserve markers)
Time Frame
18 months
Title
number of adverse effects on fertility (state of the uterine cavity)
Time Frame
18 months
Title
number of adverse effects on fertility (state of the endometrium
Time Frame
18 months
Title
Improvement of symptoms related to fibroids With UFS-QoL questionnaires
Time Frame
3 months
Title
Improvement of symptoms related to fibroids With UFS-QoL questionnaires
Time Frame
6 months
Title
Improvement of symptoms related to fibroids With UFS-QoL questionnaires
Time Frame
12 months
Title
Improvement of symptoms related to fibroids With UFS-QoL questionnaires
Time Frame
18 months
Title
Quality of life With QSF questionnaires, a French version of the WHQ questionnaire
Time Frame
3 months
Title
Quality of life With QSF questionnaires, a French version of the WHQ questionnaire
Time Frame
6 months
Title
Quality of life With QSF questionnaires, a French version of the WHQ questionnaire
Time Frame
12 months
Title
Quality of life With QSF questionnaires, a French version of the WHQ questionnaire
Time Frame
18 months
Title
Number of adverse effects during pregnancy : Rate of Miscarriage
Time Frame
Until 30 months
Title
Number of adverse effects during pregnancy : extra-uterine pregnancy
Time Frame
until 24 months
Title
Number of adverse effects during pregnancy : small for gestational age
Time Frame
Until 30 months
Title
Number of adverse effects during pregnancy : foetal death
Time Frame
Until 30 months
Title
Number of adverse effects during pregnancy : uterine rupture
Time Frame
Until 30 months
Title
Number of adverse effects during pregnancy : abnormal placental position and implantation
Time Frame
Until 30 months
Title
Number of adverse effects during pregnancy : preterm delivery
Time Frame
Until 29 months
Title
Number of adverse effects during pregnancy : delivery hemorrhagy
Time Frame
Until 30 months
Title
number of adverse effects in the newborn
Description
Rate of small for gestational age, delivery presentation, health of newborn children (Apgar score, cord pH, admission in the neonatology service)
Time Frame
At day 3 of life

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
43 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women aged ≥ 18 and ≤ 43 years old At least one interstitial fibroid more than 3 cm on MRIat MRI) with symptoms: genital bleeding, chronic pelvic pain or heaviness, anemia, or infertility > 1 year. With immediate desire to conceive without assisted reproductive indication: no tubal infertility, menstrual irregularities, hydrosalpinx, endometriosis, adenomyosis, or male infertility. Patient with health insurance, who can read and understand French and who has given written consent Exclusion Criteria: Ongoing regnancy Emergency Situation Contraindication to surgery or uterine embolization: allergy to contrast medium , renal failure, immunodeficiency, contraindication to anesthesia, subserosal or submucosal pedunculated fibroids, fibroids with largest diameter inside of the uterine cavity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antoine Torre, MD, PhD
Organizational Affiliation
Faculté de médecine de Montpellier-Nîmes, Université de Montpellier 1, France.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Arnaud Fauconnier, MD, PhD
Organizational Affiliation
UFR des sciences de la santé Simone Veil, Université de Versailles Saint Quentin en Yvelines, France.
Official's Role
Study Director
Facility Information:
Facility Name
Département de Médecine de la Reproduction, Centre Hospitalier Régionnal Universitaire de Montpellier
City
Montpellier
ZIP/Postal Code
34000
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22592701
Citation
Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2012 May 16;(5):CD005073. doi: 10.1002/14651858.CD005073.pub3.
Results Reference
background
PubMed Identifier
24430777
Citation
Torre A, Paillusson B, Fain V, Labauge P, Pelage JP, Fauconnier A. Uterine artery embolization for severe symptomatic fibroids: effects on fertility and symptoms. Hum Reprod. 2014 Mar;29(3):490-501. doi: 10.1093/humrep/det459. Epub 2014 Jan 15.
Results Reference
background
PubMed Identifier
17943348
Citation
Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol. 2008 Jan-Feb;31(1):73-85. doi: 10.1007/s00270-007-9195-2. Epub 2007 Oct 18.
Results Reference
background

Learn more about this trial

Fertility After Myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids

We'll reach out to this number within 24 hrs